Main objective: The study has been designed to assess the efficacy of blood pressure (BP) reduction in the prevention of stroke in patients with a history of ischaemic stroke, haemorrhagic stroke, or transient ischaemic attack. Study design: A randomised, double-blind, placebocontrolled, international, multicentre trial of the angiotensin-converting enzyme (ACE) inhibitor perindopril, alone or in combination with the diuretic indapamide, in the secondary prevention of stroke and other major cardiovascular events. Methodology: A total of 6000 normotensive or hypertensive patients with a history of stroke or transient cerebral ischaemia within the previous 5 years will be included in the study. The study is being conducted in over 160 centres located in seven regions: Australia and New Zealand; The People's Republic of China; France and Belgium; Italy; Japan; Sweden; and the United Kingdom. The primary study outcome is the total number of strokes defined by WHO criteria. Secondary outcomes
Introduction
There is a strong and continuous association between the level of blood pressure (BP) and the incidence of stroke. 1, 2 There is no defined threshold below which the risk of cerebrovascular accidents does not continue to decline. Data from the UK Transient Ischaemic Attack (UK-TIA) Aspirin Trial show that the relationship between BP and stroke, in individuals with a history of stroke or transient ischaemic attack (TIA), is similar to that found in individuals without a history of CV disease. 3 As predicted by epidemiological studies, 1 controlled trials of anti-hypertensive therapy in patients with hypertension have demonstrated the reduction in risk of primary stroke. 4 The same has been suggested for the patients with a history of CV disease. However, complete data are available from only four trials to address this question (two in normotensive and two in hypertensive patients), all with a limited number of participants. The combined results of these trials seem promising, but are not conclusive (reference 5, Conclusions: The viability of the study is now assured, with almost 90% of 6000 patients recruited. ACE therapy with perindopril is well tolerated in the studied population. The BP differences between control and treatment groups and the event rates recorded to date suggest that the study will achieve its primary objectives.
pp 31-38). 5 Therefore, further information is needed about the effects of BP-lowering therapy in patients with CV disease. This is the background for the large prospective randomised placebo-controlled trial PROGRESS (Perindopril pROtection aGainst REcurrent Stroke Study). The study was designed to resolve the unanswered clinical questions concerning benefits of BP-lowering therapy in this very high-risk population. 6 The primary aim is to define precisely the net effect of an angiotensin-converting enzyme (ACE) inhibitor-based BP-lowering regimen, on the risk of secondary stroke in patients with nondisabling CV disease. Since epidemiological studies indicate that BP reduction should be beneficial in terms of secondary prevention within a wide range of BPs (from as low as 75 mm Hg diastolic BP), the PROGRESS population comprises both normotensive and hypertensive individuals with a history of stroke.
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Subjects and methods
Study population
The PROGRESS study will include a total number of 6000 high-risk patients with a history of stroke (both ischaemic and haemorrhagic) or TIA. Collabor-ating centres are located in Australia, Belgium, China, France, Japan, Italy, New Zealand, Sweden, and the United Kingdom.
The study entry criteria, based on clinical evaluations are TIA (including amaurosis fugax), cerebral infarction, cerebral haemorrhage, or stroke of unknown type, within the past 5 years. Both normotensive and hypertensive individuals are eligible for inclusion. Subjects on anti-hypertensive therapy at study entry are eligible, provided their BP is well controlled and they are unlikely to receive ACE inhibitor therapy during follow-up. Patients with a clear indication for treatment with an ACE inhibitor (eg, heart failure) or a clear contraindication to ACE inhibitor therapy are excluded from the study. In effect, a patient is eligible if the doctor responsible is uncertain as to the balance of benefits and risks of ACE 1 treatment for that particular patient.
Study treatments
To identify non-compliant patients and patients not tolerating treatment with perindopril, and to reduce the risk of withdrawal after entry to the study, there is a 4-week run-in period before randomisation. Potentially eligible participants receive, in an open manner, active treatment (perindopril, 2 mg daily for 2 weeks and 4 mg daily for 2 weeks). Patients successfully completing the initial phase are then randomised to either a combination of perindopril (4 mg daily) + indapamide (2.5 mg daily; Japan 2 mg daily) or double matching placebos. Where there are contraindications to indapamide or the presence of a diuretic in the prestudy treatment, the treatment comprises either perindopril or single placebo.
Study outcomes
The primary outcome of the study is the incidence of fatal and non-fatal strokes, as defined by the World Health Organization criteria. Secondary outcomes include the following: fatal or disabling stroke; total serious cardiovascular events (stroke, myocardial infarction, or cardiovascular death); loss of cognitive function; dementia (assessed at annual visits, with the Mini-Mental State Examination); disability; and dependency. Patients will be followed up at visits scheduled at 2 weeks, 1, 3, 6, 9, and 12 months and thereafter every 6 months, for a minimum of 4 years following randomisation.
Three additional subinvestigations are being performed during the course of the study: (i) a genetic substudy seeking the association between selected genotypes and the risk of secondary stroke and progression of cognitive impairment; (ii) an MRI study assessing the effect of study treatment on whitematter lesions (study conducted exclusively in France); and (iii) evaluation of the significance of biochemical and haematological prognostic parameters in a population with a history of cerebrovascular disorders.
On the basis of previous studies, an annual stroke rate of 1.5% to 2% among controls and at least 4 mm Hg average diastolic BP difference between active treatment and placebo groups were expected, throughout 4 to 5 years of follow-up. This was the basis for estimation of the sample size of 6000 participants which would ensure at least 90% power to detect a 30% reduction in total incidence of stroke (2P = 0.05).
Results
Recruitment status by 27 March 1997
As of 27 March 1997, a total of 173 centres were registered for recruitment. By the end of June 1997, recruitment of 6000 patients should be completed. The baseline characteristics of 5268 patients randomised by 27 March 1997 is presented in the Table 1 .
Postrandomisation period to 27 March 1997
Blood pressure: As of the end of March 1997, 725 patients had completed the 6-month follow-up visit at which the BP difference between treatment and control groups was 10.2 mm Hg systolic and 4.5 mm Hg diastolic. Events: With the average follow-up of 3 to 4 months, at this early stage of the study, a total of 83 major cardiovascular events have been recorded (63 total strokes and 20 myocardial infarctions). This translates into the annual stroke rate of approximately 4% which exceeds the rate of 1.5-2% used in our original projections.
Discussion
The data collected so far clearly indicate the feasibility of the study. Its viability is now assured with more than 5000 participants recruited. As projected in the protocol, about half of the participants have a history of hypertension. The difference in BP between intervention vs control group of 10.2/4.5 mm Hg is satisfactory and consistent with the minimum required difference of 7/4 mm Hg. One should bear in mind, however, that these data are derived from follow-up of only 750 participants at 6 months, ie, on a small percentage of the total patient population. The rate of non-compliance is well below the threshold that would endanger the conduct of the study, and indicates a good tolerance of perindoprilbased therapy. The initial estimation of the stroke rate in the protocol was somewhat conservative (1.5% to 2% annually) and much lower than that found in the literature. The annual stroke rate of about 4%, observed in this trial, corresponds to the rate noted in the UK-TIA trial, where the reported incidence of recurrent stroke was 5% in the first year after an index event, and 3% in the next 4 years of followup. 3 If the event rate was maintained throughout the whole period of follow-up, the study would certainly have a satisfactory power to detect a 30% reduction in the number of strokes. These data suggest that PROGRESS should achieve its targets successfully and results should be available by June 2001.
